Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Lundbeck
  6. Summary
    LUN   DK0061804697

LUNDBECK

(LUN)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-08-09 am EDT
33.56 DKK   +1.68%
07/26LUNDBECK : Conducting largest study ever to observe early-stage multiple system atrophy
PU
07/13Lundbeck A/S - Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
AQ
07/12Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
35.3(c) 35.1(c) 34.26(c) 33(c) 33.555 Last
145 697 172 763 125 147 297 258 226 432 Volume
+1.69% -0.57% -2.39% -3.68% +1.68% Change
More quotes
Estimated financial data (e)
Sales 2022 17 350 M 2 383 M 2 383 M
Net income 2022 1 524 M 209 M 209 M
Net Debt 2022 2 194 M 301 M 301 M
P/E ratio 2022 -
Yield 2022 -
Sales 2023 18 941 M 2 601 M 2 601 M
Net income 2023 2 543 M 349 M 349 M
Net cash position 2023 1 415 M 194 M 194 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 33 677 M 4 625 M 4 625 M
EV / Sales 2022 2,07x
EV / Sales 2023 1,70x
Nbr of Employees 5 353
Free-Float 30,7%
More Financials
Company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression... 
Read more
Sector
Pharmaceuticals
Calendar
08/17Earnings Release
More about the company
Ratings of Lundbeck
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about LUNDBECK
07/26LUNDBECK : Conducting largest study ever to observe early-stage multiple system atrophy
PU
07/13Lundbeck A/S - Transactions with shares and linked securities in H. Lundbeck A/S made b..
AQ
07/12Transactions with shares and linked securities in H. Lundbeck A/S made by executives an..
AQ
06/27TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
06/27CORRECTION ( : Markets-Morning UPDATE1:)
AQ
06/27H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agi..
CI
06/26Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation ..
AQ
06/20Otsuka's European Unit Gets Clearance to Market Schizophrenia Drug
MT
06/17European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectab..
CI
06/16Results from the DELIVER study with Vyepti® has been published in a top-ranking medical..
AQ
06/16H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti
CI
06/14H. LUNDBECK A/S(CPSE : HLUN A) added to OMX Nordic All-Share Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to OMX Nordic All-Share Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
CI
More news
News in other languages on LUNDBECK
06/27POINT SUR LES FORTES VARIATIONS DU J : Prosus s'éloigne de Tencent
06/27H. Lundbeck A/S et Otsuka Pharmaceutical annoncent des résultats positifs montrant une ..
06/17L'Agence européenne des médicaments commence l'examen de l'injectable à action prolongé..
06/16H. Lundbeck A/S annonce les résultats de l'étude Deliver avec Vyepti
06/15L'agenda di oggi
More news
Analyst Recommendations on LUNDBECK
More recommendations
Chart LUNDBECK
Duration : Period :
Lundbeck Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUNDBECK
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 33,00 DKK
Average target price 190,00 DKK
Spread / Average Target 476%
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders Götzsche Chief Financial Officer & Executive Vice President
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LUNDBECK-2.28%4 625
JOHNSON & JOHNSON0.02%447 486
ELI LILLY AND COMPANY9.51%287 428
PFIZER, INC.-16.56%278 132
ROCHE HOLDING AG-16.68%273 741
ABBVIE INC.1.95%248 135